About Lucid Diagnostics
Lucid Diagnostics is a company based in New York (United States) founded in 2018. The company has 72 employees as of December 31, 2024. Lucid Diagnostics has completed 1 acquisition, including CapNostics. Lucid Diagnostics offers products and services including EsoGuard and EsoCheck. Lucid Diagnostics operates in a competitive market with competitors including PAVmed, Previse, Cyted, BeamLine Diagnostics and CapNostics, among others.
- Headquarter New York, United States
- Employees 72 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Lucid Diagnostics Inc.
-
Annual Revenue
$4.35 M (USD)79as on Dec 31, 2024
-
Net Profit
-$45.53 M (USD)13.55as on Dec 31, 2024
-
EBITDA
-$44.88 M (USD)2.39as on Dec 31, 2024
-
Latest Funding Round
$5 M (USD), Post-IPO
Oct 18, 2023
-
Investors
Not available
-
Employee Count
72
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Lucid Diagnostics
Lucid Diagnostics is a publicly listed company on the NASDAQ with ticker symbol LUCD in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Lucid Diagnostics
Lucid Diagnostics offers a comprehensive portfolio of products and services, including EsoGuard and EsoCheck.
DNA test for early detection of esophageal precancer without endoscopy.
Tool for identifying esophageal precancer risks in office visits.
People of Lucid Diagnostics
Unlock access to complete
Unlock access to complete
Funding Insights of Lucid Diagnostics
Investments & Acquisitions by Lucid Diagnostics
Lucid Diagnostics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include CapNostics.
Investment portfolio details for Lucid Diagnostics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
FDA-cleared swallowable device is used for non-endoscopic GI screening.
|
Locked | Locked | 2013 | Locked |
Complete acquisition details for Lucid Diagnostics
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Lucid Diagnostics
Detailed financials for Lucid Diagnostics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Lucid Diagnostics Comparisons
Peer comparison for Lucid Diagnostics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Lucid Diagnostics
Lucid Diagnostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as PAVmed, Previse, Cyted, BeamLine Diagnostics and CapNostics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of medical devices and biomarkers to detect various diseases
|
|
| Locked | Locked | Locked |
Cancer detection and prevention solutions are developed by Previse.
|
|
| Locked | Locked | Locked |
Non-endoscopic diagnostics for early gastrointestinal disease detection are developed.
|
|
| Locked | Locked | Locked |
Offers bedside pre-screening technology solutions for cancer detection.
|
|
| Locked | Locked | Locked |
FDA-cleared swallowable device is used for non-endoscopic GI screening.
|
Detailed competitors of Lucid Diagnostics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Lucid Diagnostics
Complete news archive for Lucid Diagnostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Lucid Diagnostics
Lucid Diagnostics was founded in 2018 and raised its 1st funding round 5 years after it was founded.
Lucid Diagnostics is headquartered in New York, United States. It is registered at New York, New York, United States.
As of Dec 31, 2024, the latest employee count at Lucid Diagnostics is 72.
Annual revenue of Lucid Diagnostics is $4.35M as on Dec 31, 2024.
Lucid Diagnostics was founded in 2018 in New York, United States, within the medical diagnostics sector. A non-invasive testing platform is provided by the company to identify esophageal cancer biomarkers. EsoGuard is employed to detect 31 methylated DNA markers associated with Barretts esophagus. EsoCheck functions as a device for collecting targeted esophageal cells. Operations focus on advancing early detection methods for gastrointestinal conditions.
Lucid Diagnostics offers EsoGuard and EsoCheck.
Yes, Lucid Diagnostics is publicly traded on NASDAQ under the ticker symbol LUCD.
Lucid Diagnostics has made 1 acquisition, including CapNostics.
The ticker symbol of Lucid Diagnostics is LUCD on NASDAQ.